Royal Bank Of Canada Hepion Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

  • $425 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.51 - $10.4 $247 - $5,044
485 New
485 $0

About Hepion Pharmaceuticals, Inc.

HEPA Quotes by TradingView
  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $57.2M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email